IRDAI’s proposed commission caps could squeeze Policybazaar and Turtlemint
Proposed IRDAI commission caps may cut Policybazaar’s new-health insurance commissions by 33%–50%, pressuring insurance-distribution economics. PB Fintech expects volatility through FY28 before a potential recovery in FY29; comments are due October 25, 2026.
The development
IRDAI proposed on September 23 commission caps that could cut Policybazaar’s new-health commissions by 33%-50%, threatening its insurance-distribution model. PB Fintech reported ₹162.9 Cr Q1 FY27 net profit, while Turtlemint faces greater exposure from general insurance.
The numbers
- ₹20,000
- September 23
- 12.5%
- 20%
- 30%
- FY23
- FY25
- 125%
- 28%
- ₹48,000 Cr
- FY21
- ₹1.08 Lakh Cr
- ₹162.9 Cr
- ₹84.7 Cr
- 40%
- ₹1,888.3 Cr
- ₹1,348 Cr
- Q1 FY27
- Q1 FY26
- 18.5%
- 33%-50%
- 34-36%
- 52-week
- 50:50
- ₹1,003 Cr
- 55%
- 59%
- 25% to 33%
- 15–20%
- 60%
- 35.98%
- ₹1,210
- ₹55,993 Cr
- ₹109.04
- ₹2,310
- 10%
- 10–12%
- 70–90%
- FY28
- FY29
- 90%
- 5%
- 77.45%
- 6.21%
- 5.3%
- ₹1,510.1 Cr
- ₹1,430 Cr
- $2 Bn-$2.5 Bn
- H1 2027
- FY26
- October 25, 2026
Why it matters to operators and investors
The regulatory squeeze could spur partnerships, consolidation, or capability acquisitions among insurance distributors seeking scale, lower-cost distribution, and less commission-dependent revenue streams.
What to watch next
- Final IRDAI wording after the October 25, 2026 consultation deadline, especially product-level caps, transition periods, and treatment of renewal commissions.
- PB Fintech guidance on health new-business margins, customer-acquisition cost, renewal revenue mix, and FY27-FY29 profitability assumptions.
- Turtlemint disclosures on general-insurance gross written premium growth, insurer compensation rates, and agent retention.
- Insurer premium repricing, changes in online-versus-offline distribution mix, and any increase in direct-to-consumer marketing.
- Evidence of alternative compensation structures such as service fees, technology fees, persistency bonuses, or claims-performance incentives.
- Policybazaar is likely to reallocate acquisition spend toward renewal-heavy, higher-persistency health customers and cross-sell credit, term-life, and service products.
- Turtlemint may push insurers for technology, claims-support, and performance-linked fee arrangements while pruning lower-margin general-insurance distribution channels.
- Insurers may internalize more digital lead generation, favor captive or preferred distributors, and redesign product pricing to recover some distribution-cost savings.
- Both platforms may accelerate B2B2C, embedded-insurance, and advisory/service revenue to reduce dependence on upfront commissions.
- Smaller brokers and agent-led intermediaries could face consolidation pressure if they lack scale, renewal books, or insurer bargaining power.
The counter-case
The headline may overstate the earnings damage: commission caps could be offset by higher policy volumes, better renewal economics, insurer-funded technology/service fees, or a shift toward products with less severe caps. Large platforms such as Policybazaar may gain share if smaller intermediaries cannot absorb lower commissions, while insurers may still pay for customer acquisition through permitted channels. The FY29 recovery framing is also speculative until the final rules, effective date, and transition provisions are known.